Experienced in Togaviridae Disease

Dr. William P. Jennings

Internal Medicine
8122 Datapoint Dr, Suite 1010, 
San Antonio, TX 
Experienced in Togaviridae Disease
8122 Datapoint Dr, Suite 1010, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Jennings is a primary care provider, practicing in Internal Medicine in San Antonio, Texas. Dr. Jennings is rated as an Experienced provider by MediFind in the treatment of Togaviridae Disease. His top areas of expertise are Chronic Pain, Togaviridae Disease, Neuralgia, and Mumps.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Togaviridae Disease.

Specialties
Internal Medicine
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

8122 Datapoint Dr, Suite 1010, San Antonio, TX 78229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: November 30, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Terminated
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

2 Total Publications

Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations.
Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations.
Journal: Current gastroenterology reports
Published: May 24, 2025
Similar Doctors
Experienced in Togaviridae Disease
Dr. Robert V. Gibbons
Internal Medicine
Experienced in Togaviridae Disease
Dr. Robert V. Gibbons
Internal Medicine
3698 Chambers Pass Bldg 3611, Us Army Institute Of Surgical Research, 
Jbsa Ft Sam Houston, TX 
 (8.7 miles away)
210-636-4424
Languages Spoken:
English

Robert Gibbons is a primary care provider, practicing in Internal Medicine in Jbsa Ft Sam Houston, Texas. Dr. Gibbons is rated as a Distinguished provider by MediFind in the treatment of Togaviridae Disease. His top areas of expertise are Dengue Fever, Viral Hemorrhagic Fever, Japanese Encephalitis, and Flu.

Experienced in Togaviridae Disease
Dr. Akhtar A. Hussain
Internal Medicine
Experienced in Togaviridae Disease
Dr. Akhtar A. Hussain
Internal Medicine
10823 Town Ctr Dr, 
San Antonio, TX 
 (8.2 miles away)
210-509-7462
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Akhtar Hussain is a primary care provider, practicing in Internal Medicine in San Antonio, Texas. Dr. Hussain is rated as an Advanced provider by MediFind in the treatment of Togaviridae Disease. His top areas of expertise are Acute Kidney Failure, Osteoarthritis, Interstitial Nephritis, Small Bowel Resection, and Endoscopy. Dr. Hussain is currently accepting new patients.

Experienced in Togaviridae Disease
Dr. Robert T. Ching
Internal Medicine
Experienced in Togaviridae Disease
Dr. Robert T. Ching
Internal Medicine

Robert Ching Do PA

7115 Fairlawn Dr, 
San Antonio, TX 
 (14.0 miles away)
210-337-2600
Languages Spoken:
English, Mandarin, Spanish
See accepted insurances
Accepting New Patients

Robert Ching is a primary care provider, practicing in Internal Medicine in San Antonio, Texas. Dr. Ching is rated as a Distinguished provider by MediFind in the treatment of Togaviridae Disease. His top areas of expertise are High Cholesterol, Type 2 Diabetes (T2D), Glucocorticoid-Remediable Aldosteronism, and Familial Hypertension. Dr. Ching is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jennings's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile